Cover Image

Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfection

Saved in:

Bibliographic Details
Main Authors:	Xiaosu Chen (Author), Yanli Xu (Author), Yan Xie (Author), Weiliang Song (Author), Ye Hu (Author), Ayijiang Yisimayi (Author), Sijie Yang (Author), Fei Shao (Author), Li Geng (Author), Ying Wang (Author), Hongmei Gao (Author), Yansong Shi (Author), Shuo Zhang (Author), Ronghua Jin (Author), Zhongyang Shen (Author), Yunlong Cao (Author)
Format:	Book
Published:	Elsevier, 2023-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection
by: Jin-Jin Chen, et al.
Published: (2023)

The epidemiology and phylogenetic trends of Omicron subvariants from BA.5 to XBB.1 in Taiwan
by: Jih-Jin Tsai, et al.
Published: (2024)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
by: Cong Xu, et al.
Published: (2023)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
by: Wanting Li, et al.
Published: (2023)

An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China
by: Meiling Zhang, et al.
Published: (2022)

As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?
by: Ren Xu, et al.
Published: (2022)

Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study
by: Cheng Cao, et al.
Published: (2023)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
by: Rachael Pung, et al.
Published: (2023)

Statement on healthcare system preparedness in response to COVID-19 Omicron subvariants BA.4 and BA.5 surge in Korea from the Korean Pediatric Society and Korean Society of Pediatric Infectious Diseases
by: Eun Young Cho, et al.
Published: (2022)

SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil.
by: Francisco P Freire-Neto, et al.
Published: (2022)

The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China
by: Jinjin Chu, et al.
Published: (2024)

COVID-19 hospitalisations in a tertiary health service during the Omicron subvariant wave
by: Alysha Y. Wanigaratne, et al.
Published: (2024)

The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees
by: Francesca Dapporto, et al.
Published: (2022)

Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak
by: Wenjing Ye, et al.
Published: (2023)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
by: Srijan Chatterjee, et al.
Published: (2023)

Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection
by: Huiling Zheng, et al.
Published: (2024)

Clinical Profile and Outcome Analysis of Ear-Nose-Throat Symptoms in SARS-CoV-2 Omicron Subvariant Infections
by: Yixuan Liu, et al.
Published: (2023)

Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
by: Weiyu Peng, et al.
Published: (2023)

Characteristics of Omicron variant-induced SARS-CoV-2 reinfections in Chengdu, China
by: Yingxue DAI, et al.
Published: (2023)

SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period
by: Su Lan Yang, et al.
Published: (2022)

Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants
by: Chiranjib Chakraborty, et al.
Published: (2023)

Serum neutralizing capacity and T-cell response against the omicron BA.1 variant in seropositive children and their parents one year after SARS-CoV-2 infection
by: Alina Seidel, et al.
Published: (2023)

Immediate reinfection with Omicron variant after clearance of a previous SARS-CoV-2 infection
by: Antonella Mencacci, et al.
Published: (2022)

Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant
by: Anita M. Shete, et al.
Published: (2022)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
by: Freja Cordelia Møller Kirsebom, et al.
Published: (2022)

Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants
by: Sivaprakasam T. Selvavinayagam, et al.
Published: (2022)

Smoking cessation in the elderly as a sign of susceptibility to symptomatic COVID-19 reinfection in the United States
by: Wataru Ando, et al.
Published: (2022)

Prevalence of SARS-CoV-2 Omicron variants and epidemiological characteristics of subvariant XBB infections in Pudong New Area, Shanghai during January - June 2023
by: Yilin JIA, et al.
Published: (2023)

Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127
by: Chengzhuo Tong, et al.
Published: (2022)

SARS-CoV-2 reinfection with Omicron variant in Shaanxi Province, China: December 2022 to February 2023
by: Mengyan Zhang, et al.
Published: (2024)

Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2: A Single-Center Retrospective Study in Saudi Arabia
by: Abeer N. Alshukairi, et al.
Published: (2023)

Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76
by: Urvashi B. Singh, et al.
Published: (2023)

Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
by: Line Lundegaard Bang, et al.
Published: (2024)

Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland
by: Steven Kerr, et al.
Published: (2022)

Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1/BA.2 and BA.5-predominant periods in Japan
by: Kimiko Tomioka, et al.
Published: (2023)

Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2
by: Weijie Zhong, et al.
Published: (2023)

Factors associated with delayed diagnosis of symptomatic adult COVID-19 cases presenting to primary care: a population-wide study during transition from Delta to Omicron BA.1 in SingaporeResearch in context
by: Ren Ying Tan, et al.
Published: (2023)

Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
by: Haruka Maeda, et al.
Published: (2023)

Severity of Omicron BA.5 variant and protective effect of vaccination: national cohort and matched analyses in Scotland
by: Chris Robertson, et al.
Published: (2023)

Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico
by: José Antonio Montes-González, et al.
Published: (2023)